Viral vectors play important roles in traditional CAR-T cell therapy nowadays. Although they are promising, imitations still exist. Firstly, using viral vector carries a risk of insertional oncogenesis or clonal dominance. Meanwhile, when administered directly in vivo, viral vectors may cause unwanted immunogenicity. Moreover, it is cumbersome and costly for the manufacturing of viral vector since living cells are required and the quality control is complicated as well as the downstream processing. Therefore, we bring out the SB transposon system as an alternative of viral vectors to circumvent some of these limitations. Learn more:
Sleeping Beauty system for CAR-T